Drug Addiction Science and the U.S. Overdose Epidemic

Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse email: wcompton@nida.nih.gov



Disclosures of Interests: Wilson M. Compton, MD, MPE

• Stock Equity:

- 3M Company (under \$5,000)
- General Electric Corporation (under \$5,000)
- Pfizer, Inc. (under \$5,000)
- Speaker's Bureau(s): None
- Sources of Research Support: NIH
- Consulting Relationships: None
- Current Position: Deputy Director, National Institute on Drug Abuse

Virtually all U.S. regions have experienced rising overdose death rates over the past two decades.


106,699 reported deaths in 2021 80,411 from Opioids (Prescription and Illicit)


111,355 predicted deaths over past 12 months (as of April 30, 2023, *provisional data*)

National Center for Health Statistics, National Vital Statistics System, mortality data https://www.cdc.gov/nchs/data-visualization/drug-poisoning-mortality/

Additional Consequences of Addiction

- Drug use while pregnant or parenting has led to increases in rates of neonatal abstinence syndrome and removal of children into the foster care system.
- Increased rates of injection drug use have led to increases in acute cases of Hepatitis C and outbreaks of HIV







Note: Final and provisional data cannot be compared because final data includes deaths reported in US residents, whereas provisional data includes all deaths in the US including those in foreign residents. Provisional data is included here to provide a sense of what the final data may show. **Source**: The Multiple Cause of Death data are produced by the Division of Vital Statistics, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), United States Department of Health and Human Services (US DHHS).

Economics: Current Opioid Crisis Originated with Prescribing Increases

Opioid prescriptions *Tripled to MORE THAN* 200 MILLION prescriptions in the 2000's








Economic Drivers: Cheap precursors = fentanyl's dominance

Criminal Chemistry

Traffickers manufacturing fentanyl often purchase the key ingredient from China, which doesn't regulate its sale. Here's how the chemical building blocks become a highly profitable street drug.



**Average current price from Chinese suppliers **Price Sources: NES Inc.; Drug Enforcement Administration; Calgary Police

THE WALL STREET JOURNAL.

September 27, 2021


DEA Issues Public Safety Alert on Sharp Increase in Fake Prescription Pills Containing Fentanyl and Meth



DEA Warns that International and Domestic Criminal Drug Networks are Flooding the United States with Lethal Counterfeit Pills


https://www.dea.gov/press-releases/2021/09/27/dea-issuespublic-safety-alert

Number of Pills Containing Fentanyl Seized by Law Enforcement in the United States, 2018 – 2021



Estimates based on data reported by the Office of National Drug Control Policy's High Intensity Drug Trafficking Areas program

Reference: JJ Palamar, et al. Drug and Alcohol Dependence. DOI: 10.1016/j.drugalcdep.2022.109398 (2022)



National Vital Statistics System multiple-cause-of-death 2015-2020 final and 2021 provisional data U.S. census monthly data. II: Joinpoints indicate significant changes in nonlinear trends using Bayesian Information Criterion. AQPC=average quarter percentage change during 2015 Q1-2022 Q2. ICD-10 cause of death code: synthetic opioids other than methadone (T40.4, primarily fentanyl and analogs).

Illicit Drug Supply Evolves

States with at least one positive xylazine detection, 2019-2021



Jan 2020



Jun 2021



Xylazine

- Alpha-2 adrenergic agonist used as a veterinary sedative
- Inhibits release of norepinephrine, decreasing sympathetic activity
- When combined with Fentanyl, it appears to extend the duration of their pharmacological effects (analgesia, respiratory depression, reward)
- Toxic doses in humans range from 40 to 2400 mg (0.6-34.3 mg/70 kg)
- Associated with severe tissue injury
- Appears nearly always in combination with fentanyl
- Not reversed by naloxone, but fentanyl is reversed by naloxone Kacinko, S et al., J Analytical Toxicology, 46(8), 911-917.

White House Office of National Drug Control Policy: FENTANYL ADULTERATED OR ASSOCIATED WITH XYLAZINE RESPONSE PLAN (released July 2023)

https://www.whitehouse.gov/wp-content/uploads/2023/07/FENTANYL-ADULTERATED-OR-ASSOCIATED-WITH-XYLAZINE-EMERGING-THREAT-RESPONSE-PLAN-Report-July-2023.pdf

Other drugs/contaminants also appearing...

Nitazenes

- July 2019—Isotonitazene found in U.S. toxicology and >250 overdose deaths
- August 2020—DEA classified isotonitazene as a Schedule I substance and listed in Annual Emerging Threat Report; other nitazines (e.g., etonitazene and metonitazene) emerge
- Nitazenes detected postmortem in combination with other drugs, 2021


Tianeptine

- Antidepressant drug that is not approved by the Food and Drug Administration (FDA). Clinical effects of tianeptine abuse and withdrawal can mimic opioid toxicity and withdrawal.
- Tianeptine exposure calls to U.S. poison control centers increased during 2014– 2017, suggesting a possible emerging public health risk.
- Associated health effects included neurologic, cardiovascular, and gastrointestinal signs and symptoms, with some effects mimicking opioid toxicity and withdrawal.


Point of care testing (e.g., urine drug screen for fentanyl or other opioids) does not detect nitazenes or tianeptine which require labbased mass spectrometry testing that is not widely available.

Need for development of specialized detection assays?

U.S. Department of Health and Human Services (HHS): Overdose Prevention Strategy Pillars and Cross-Cutting Principles



Social Determinants of Health (SDOH), including adverse childhood experiences, play a role in substance use and addiction.




Dube, et al. Pediatrics (2003)

ACE account for one half to two thirds of serious problems with drug use.

Modifying Environmental Risks:

A family-based intervention for teens reduces substance use and may help prevent changes in brain development associated with poverty.




SAAF=Strong African American Families intervention

Brody, et al. *Pediatrics* (2012)

Universal Substance Use Prevention May Reduce Later Use of Opioids & Methamphetamine

Targeting Youth to Prevent Later Substance Use Disorder: An Underutilized Response to the US Opioid Crisis

WM Compton, CM Jones, GT Baldwin, et al. *AJPH.* 2019;109:2185-S189.



Note: Study 2 included both ISFP and LST interventions RL Spoth, et al. (2006) Arch Pediatr Adolesc Med.

Access to Naloxone

2014 FDA approves naloxone *autoinjector* with a prescription.
2015 FDA approves *nasal naloxone* spray with a prescription.
On March 29, 2023, FDA approved the first nasal naloxone spray available *without a prescription*.

On May 22, 2023, FDA approved *nalmefene nasal* spray *with a prescription*.

On July 28, 2023, FDA approved the first *generic* nasal naloxone spray *without a prescription*.

Inexpensive *injectable* naloxone widely available as well.

HealthAffairs

Making Addiction Treatment More Realistic And Pragmatic: The Perfect Should Not Be The Enemy Of The Good

Nora D. Volkow

"The magnitude of this crisis demands outof-the-box thinking"

"Drug addiction is a chronic but treatable disorder with well-understood genetic and social contributors. It is not a sign of a person's weakness or bad character."

"Continued or intermittent use of drugs, even by people who know they have a disorder and are trying hard to recover from it, must be acknowledged as part of the reality of the disorder for many who struggle with it."



New Harm Reduction Research Network

Goal: To increase our understanding of the effectiveness, implementation, and impact of existing and new harm reduction practices for people with SUD.

Priorities

- Novel harm reduction approaches
- Novel settings and modes of delivery
- Understanding and addressing barriers
- Ensuring access and benefits for vulnerable, understudied, and hard-toreach populations
- Harm reduction for people who use methamphetamine and other stimulants

🔚 News Release

NIH launches harm reduction research network to prevent overdose fatalities

Scientists will test community-based approaches to prevent drug overdoses, curb high death rates

December 16, 2022

To address the overdose crisis in the United States, the National Institutes of Health has established a research network that will test harm reduction strategies in different community settings to inform efforts to help save lives. The harm reduction research network's efforts build on existing harm reduction research, and represent the



NIDA Image

largest pool of funding from NIH to date to study harm reduction strategies to address overdose deaths.

More than 107,000 people in the United States died from a drug overdose in 2021, according to provisional data from the U.S. Centers for Disease Control and Prevention. These deaths are largely driven by the proliferation of cheap, potent synthetic drugs like fentanyl contaminating the drug supply, including in heroin, cocaine, methamphetamine, and counterfeit pills.



66 Cite this article

NIDA Press Office 301-443-6245 media@nida.nih.gov 🖾


Email Updates

email address

To sign up for updates or to access your subscriber preferences, please enter your contact information below.

Subscribe

Addressing the Stigma of Addiction



Among the most harmful of these is the scientifically unfounder The addiction and overdose drug-taking by individuals with addiction reflects ongoing delibe crisis, which now claims more choices. This belief contributes to the continued criminalization than 100,000 lives a year 🔼, shows little sign of abating, and emerging d

addiction.

startling impact on pregnant people: Overdose is now a leading cause of or shortly after pregnancy.

A Witness' Story


Through Art

While attitudes around drug use, particularly use of substances

significantly changed in recent decades, the use and possessior Columbia University researchers recently reported that drug overdose of to be penalized. Punitive policies around drugs mark people wh

pregnant and postpartum people increased by 81% Z between 2017 an September 2022, the Centers for Disease Control and Prevention releas that deaths related to mental health conditions, including substance use (SUDs), account for 23% of deaths during pregnancy or in the year follow outstrips excessive bleeding, cardiovascular conditions, or other well-known

Medication treatment of OUD in the US increased from 2010 to 2019; But treatment gap is still very large




Individuals receiving pharmacy dispensed extended-release naltrexone

- Estimated annual prevalence of 7,631,804 individuals suffering from OUD (2723.5/100 000) in 2019
- Estimated number of individuals receiving medications for OUD 1,031,785 (368.2/100 000) in 2019
- Though MOUD treatment has increased in past 10 years in 2019 still only 13.4% of individuals with OUD received MOUD.



Overdose rates rose sharply for all, but especially among older Black men and Al/AN persons during the pandemic.



COVID-Related Temporary Policy Changes for Prescribing MOUD



Methadone (available only at OTPs)

Before COVID

- In-person eval at OTP required for initiation.
- In-person daily dosing required for most patients.

During COVID

- Up to 28 take-home doses for stable patients
- Up to 14 days for less stable patients

Buprenorphine (available by Rx at pharmacies)

Before COVID


- BUP prescribing limited to clinicians holding X-waivers based on DEA registration and training.
- Per physician cap on the number of patients treated with BUP at a given time.
- In-person eval required for initiation.

During COVID


Telehealth (including audio-only) allowed for initiation and follow-up.



Buprenorphine-involved overdoses remained rare and did not increase as a percentage of opioid deaths.



Take-Home Doses of Methadone Therapy Associated with Improved Outcomes



Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder (MOUD), and Medically Treated Overdose (OD) Among Medicare Beneficiaries Before and During the COVID-19 Pandemic

Characteristics Associated With MOUD Retention for at Least 80% of Eligible Days Among Beneficiaries With OUD and MOUD

Characteristic	aOR (95% CI) ^b
Total, No.	8826
Receipt of OUD-related telehealth service	1.267 (1.139-1.410) ^c

Characteristics Associated With Experiencing A Medically Attended OD During Study Period

Among Beneficiaries With OUD

Characteristic	aOR (95% CI) ^b
Total, No.	70 497
Receipt of OUD-related telehealth service	0.671 (0.634-0.710) ^c

Source: Jones CM, Shoff C, Hodges BS, Blanco C, Losby JL, Ling SM, Compton WM. JAMA Psychiatry. 2022;79(10):981-992

Characteristics Associated With Experiencing A Fatal Drug OD During Study Period Among

Beneficiaries With OUD

Characteristic	Beneficiaries, No. (%)	aOR (95% CI) ^b
Receipt of OUD-related telehealth service	13 809 (19.6)	0.67 (0.48-0.92) ^c

Source: Jones CM, Shoff C, Hodges BS, Blanco C, Losby JL, Ling SM, Compton WM. JAMA Psychiatry. 2023;80(5):508–514

NIDA Research pivots to address substance use and overdose trends.

- Treating OUD in the fentanyl era
 - Implementation and services research to expand MOUD
 - Therapeutic development: novel medications, immunotherapies, neuromodulation
 - Alternative outcomes: craving, sleep, OUD severity
- Therapeutics for StUD, polysubstance UD, co-morbidities
- Novel overdose treatments, including for stimulant OD
- Prevention of substance use and addiction
 - Social Determinants of Health
 - Pre-addiction
- More timely data on fatal and non-fatal overdoses, use patterns of emerging drugs (e.g., nitazenes, xylazine) and drug mixtures
- Harm reduction approaches and outcomes
- Recovery approaches and outcomes



Implementation Science: CTN, JCOIN, HCS, Prevention



NIH HEAL JCOIN INITIATIVE JUSTICE COMMUNITY OPIOID INNOVATION NETWORK



HEALing Communities Study


Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids Expand research conducted by NIDA CTN to address emergent needs presented by the opioid crisis. Justice Community Opioid Innovation Network Study quality care for OUD in justice populations. Help create partnerships between local and state justice systems and community-based treatment providers.

HEALing Communities Study


is investigating coordinated approaches for deploying evidence-based strategies to prevent and treat OUD in 67 communities in 4 states.

Developing Novel Approaches





Recovery is Possible:



Normal Control METH User METH User ml/gm (1 month detox) (14 months detox) Source: Volkow, ND et al., *Journal of Neuroscience* 2001

^{µmol/100g/min} Control Subject METH Use METH Use (30 y/o, Female) (27 y/o, Female) (27 y/o, Female) 3 months detox 13 months detox Improvements in Brain Metabolism with Prolonged Abstinence from Methamphetamine Use

G-J Wang et al., Am J Psychiatry 2001

Take Home Key Messages

- As the opioid epidemic continues to evolve—increases seen in synthetic opioids and polysubstance use, including opioid coinvolvement with methamphetamine use
- The COVID-19 pandemic has exacerbated the overdose crisis
- Treatment addresses the underlying neurobiology of addiction: Treatment saves lives
- New tools and targets show promise; prevention is essential
- Reducing stigma and harm reduction approaches are critical components of the HHS Overdose Prevention Strategy